Experience

OncoSil Medical

• Australia
• Medical Equipment Manufacturing
• 1 - 100 Employee

• Director Access / Reimbursement / Economics / Assessment EMEA

  • Sep 2020 - Present

  • Architect of EMEA Access / Reimbursement / Economics / Assessment / Pricing strategy including influencing the clinical evidence generation strategy to enhance the clinical body of evidence to get fit for the upcoming EU-Joint health technology assessment (HTA) evaluation and cost-effectiveness analysis (CEA) with particular focus on bias- & confounder-controlled and comparative study design, selection of standard-of-care comparator and true primary endpoint as well as statistical significance through Senior Leadership Team Membership. • Leading the development of innovation funding (NUB) requests through German hospitals to Institute for calculation of inpatient hospital reimbursement (InEK) / coverage with evidence development (CED) dossier submission to federal joint committee (GBA) (§ 137h SGB V). • Leading the development of a reimbursement dossier incl. Budget-Impact-Analysis (BIA) on ultrasound-guided endoscopic injection implantation of ³²P-labelled microparticles combined with systemic chemotherapy in treatment of primarily unresectable locally advanced pancreatic tumours and submission to the Belgian NIHDI Agency. • Exploring the French CED "forfait innovation" scheme in collaboration with KOLs and relevant medical societies for submission to the HTA Agency HAS. • Leading the preparation of an interventional procedure guidance application to the English HTA agency NICE. • Exploring the HTA and CEA-based public health insurance market access scheme conducted by the Dutch ZIN Agency with particular consideration of the CED "potentially promising care" scheme as well as the diagnosis-related groups (DRG) based hospital reimbursement in the Netherlands. • Supporting the development of a reimbursement dossier to be submitted to the Greek Ministry of Health (MoH) through a local distributor. • Supporting the development of a reimbursement dossier incl. BIA to be submitted to the Israelian MoH through a local distributor. Show less



Sirtex Medical Limited

• United States
• Medical Equipment Manufacturing
• 200 - 300 Employee

• Sr Mgr Market Access, Provider Reimbursement, Health Economics, Technology Assessment DACH

  • May 2015 - Aug 2020

  • Guiding treating physicians and medical controllers of customer hospitals to select suitable patients and document the treatment decision properly in proactive action to avoid retrospective funding denials by Statutory Health Insurances (SHI) based on expert opinions by medical review boards (MDK) in reimbursement roadshows in close collaboration with the sales colleagues and to prevent hospital administrations to order the stop of Selective Internal Radiation Therapy (SIRT) at all and secure justifiable treatment utilisations and corresponding revenue. • Consulting customer hospital solicitors in payment claims against SHIs at local, regional and national social courts in retrospective funding denial cases of SIRT treatments. • Developing a Profit-/Loss-Calculator from German Hospital Perspective on SIRT versus Transarterial Chemoembolisation (TACE) in Hepatocellular Carcinoma (HCC) Barcelona Clinic Liver Cancer (BCLC) Stage B/C. • Development of therapy / product related grouping simulations & revenue calculations as well as economical pathways based on analysis of diagnois (ICD) & procedure (OPS) coding catalogue as well as case (DRG) & supplementary (ZE) fee-based tariff. • Representing the company in the access / reimbursement working groups of the German medical device trade association (BVMed). Show less



3M (former LifeCell, part of Kinetic Concepts)

• Germany, Austria, Switzerland

• Mgr Market Access, Provider Reimbursement, Health Economics, Technology Assessment DACH

  • Apr 2011 - Apr 2015

  • Development of Budget-Impact Analysis (BIA) utilising claims data from German Public Health Insurance Perspective on implant-based breast reconstruction utilising a biological tissue for lower pole reinforcement versus various other methods of breast reconstruction after mastectomy. • Development of BIA utilising claims data from German public health insurance perspective of abdominal wall reconstruction utilising a biological tissue versus other reinforcement methods of abdominal wall reconstruction. • Training the sales, marketing, clinical and medical colleagues on the requirements of Health Technology Assessment based incremental clinical / medical patient-relevant benefit assessments and Provider Reimbursement based hospital funding system and the corresponding consequences for commercialisation and product pricing. • Representing the company in the access / reimbursement working groups of the German medical device trade association (BVMed). Show less



Medtronic

• United States
• Medical Equipment Manufacturing
• 700 & Above Employee

• Technical Consultant, Sales Representative, Reimbursement Specialist

  • May 2010 - Mar 2011

  NeurologyNeurosurgeryPain TherapyHospital (inpatient)Physician (outpatient)Active Implantable Medical Device (AIMD)Germany

• Sr Specialist Market Access, Provider Reimbursement, Health Economics, Technology Assessment

  • Aug 2000 - Apr 2010

  • Time-driven, activity-based, bottom-up, micro-costing collection and calculation of neuromodulation interventions to inform customer hospitals for appropriate DRG & ZE & NUB fee negotiations with the statutory health insurances during the annual budget negotiations.• Adjustment of diagnosis (ICD) and procedure (OPS) catalogue and case (DRG) & supplementary (ZE) fee tariff in cooperation with relevant medical societies accomplished the following results:○ 6 new ICD codes for diseases potentially treated by neuromodulation interventions○ 151 new OPS codes for neuromodulation interventions○ 30 new DRGs and ZEs including innovation funding (NUB) for inpatient services○ 24 new reimbursement codes in Uniform Value Scale (EBM) for outpatient services• Co-Development of Cost-Effectiveness-Model from German Public Health Insurance Perspective on Intrathecal Baclofen Therapy (ITB) versus Best Medical Treatment (BMT) excluding ITB in Patients with severe generalised Spasticity.• Co-Development of Budget-Impact-Model from German Public Health Insurance Perspective on Deep Brain Stimulation (DBS) versus BMT excluding DBS in Patients with advanced Parkinson’s Disease.• Development of integrated care models for DBS and ITB, acquisition of in- & outpatient physicians & hospitals & commercialisation targeted at public & private health insurances. • Collection of outstanding debts (>€2m) from SHIs resulting from outpatient neuromodulation interventions.• Training the sales, marketing, clinical and medical colleagues on the DRG & ZE fee-based hospital reimbursement system and the corresponding consequences for commercialisation and product pricing.• Representing the company in the access / reimbursement working groups of the German medical device trade association (BVMed). Show less

• Sales Representative

  • Oct 1998 - Jul 2000

  NeurologyNeurosurgeryPain TherapyHospital (inpatient)Physician (outpatient)



Medtronic (former Kendall, part of Covidien/Tyco)

• Northwest-Germany

• Sales Representative

  • Apr 1996 - Sep 1998

  Anaesthesiology Surgery Nursery Home Nursing Service Physician (outpatient) Anaesthesiology Surgery Nursery Home Nursing Service Physician (outpatient)



pfm Medical (former Dispo)

• Northwest-Germany

• Sales Representative

  • Apr 1995 - Mar 1996

  Anaesthesiology Surgery Pathology Hospital (inpatient) Physician (outpatient) Anaesthesiology Surgery Pathology Hospital (inpatient) Physician (outpatient)